Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Prepares to Test IPO Waters

NEW YORK, Jan 19 – Third Wave Technologies is planning to test the IPO waters with a roadshow that is scheduled to begin next week, a company spokeswoman said Friday.

The company is hoping to sell 8.5 million shares at $11 - $13 a share in an offering that could raise as much as $110 million for the Madison, Wis.-based maker of SNP analysis technologies.

Lehman Brothers is the lead underwriter. CIBC World Markets, Dain Rauscher Wessels, Robert W. Baird, and Fidelity Capital Markets are also underwriting the offering.

Third Wave first filed for the IPO in August, but poor market conditions have prevented the company from going public earlier.

On Friday bioinformatics company NetGenics said it was slashing its workforce by 30 percent as a result of its inability to go public due to the downturn in the markets. DoubleTwist has also delayed its IPO.

A source close to Third Wave said he was not sure whether the company would be able to fill the orders necessary to launch the offering.

“We will have to see” if they can do it, he said.

According to a recent Dow Jones report, Third Wave posted revenues of $4.9 million in the first nine months of 2000, the latest figures available, compared with $2.1 million in the corresponding period in 1999. Net losses jumped to $31.0 million in the first nine months of last year, compared with $5.6 million in the same period in 1999.

Third Wave has raised $86 million in private financing since its inception.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.